On Wednesday, Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) released Phase 2 study data from the regimen of bemnifosbuvir and ruzasvir for the hepatitis C virus infection that causes liver swelling and can lead to serious liver damage.

The study met its primary endpoints of safety and sustained virologic response at 12 weeks post-treatment (SVR12).

Primary endpoint results demonstrated a 98% (208/213) SVR12 rate in the per-protocol treatment adherent patient population after eight weeks of treatment with a regimen of bemnifosbuvir and ruzasvir.

Also Read: Atea Pharmaceuticals’ COVID-19 Treatment Flunks In Late-Stage Study, Blames’ Constantly Evolving’ Virus

The efficacy evaluable patient population, which included 17% treatment non-adherent patients, achieved a 95% (242/256) SVR12 rate demonstrating the potency and forgiveness of the regimen.

In June, Atea Pharmaceuticals shared new data from the lead-in cohort (n=60) of its ongoing Phase 2 combination study of bemnifosbuvir and ruzasvir for hepatitis C virus.

The regimen was generally safe and well-tolerated, with no drug-related serious adverse events or treatment discontinuations.

Full data for the Phase 2 study will be presented at a scientific meeting during the first half of 2025.

In the Phase 2 study, 99% (178/179) of treatment-adherent patients who were non-cirrhotic and infected with genotypes 1-4 achieved SVR12, demonstrating robust pan-genotypic potency and supporting an eight-week treatment in the Phase 3 program.

Treatment adherent patients with cirrhosis achieved a 88% (30/34) SVR12 rate.

Viral kinetics were slower in these cirrhotic patients. However, all patients achieved 100% end-of-treatment response. To maximize efficacy, the Phase 3 program will extend treatment duration to 12 weeks in patients with cirrhosis.

Atea is preparing for the Phase 3 program, which is expected to follow an End of Phase 2 meeting with the FDA anticipated for early 2025.

The Phase 3 program is expected to use a fixed-dose combination tablet, reducing the daily pill count from four to two tablets and enhancing patient convenience, with no food effect.

Price Action: AVIR stock is down 9.63% at $3.15 at the last check on Wednesday.

Read Next:

• Southland Holdings Lands $60M Wastewater Deal: Details

Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.

Get the latest stock analysis from Benzinga?

This article After Failed COVID-19 Drug Trial, Atea Pharmaceuticals Touts Encouraging Data From Mid-Stage Hepatitis C Study originally appeared on Benzinga.com

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.